Intrathecal Rituximab With Standard Intrathecal Prophylaxis to Prevent CNS Relapse for CD 20+ Non Hodgkin Lymphoma

Running, not enrolling · Phase 2

Conditions studied: Non Hodgkin Lymphoma

In brief

The purpose of this research study is to learn if giving rituximab, the study drug, right into the spinal canal along with chemotherapy drugs like methotrexate is possible and safe.

Key facts

Study ID

NCT03688451

Run by

Tahir Latif

People needed

20

Starts

2018-10-29

Expected to finish

2024-10-01

Last updated by the study team

2023-03-29

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• CD20 positive diffuse large b-cell lymphoma undergoing treatment with systemic rituximab in combination with CHOP, CHOEP, or EPOCH and deemed high risk of CNS relapse and eligible for central nervous system prophylaxis with intrathecal therapy.

You may not qualify if…

• Primary central nervous system lymphoma or established secondary central nervous system disease.
• History of spinal surgery and/or ineligible for intrathecal injections.

Where it is running

• UC Health — Cincinnati, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.